Journal of Korean Traditional Oncology (대한암한의학회지)

Korean Association of Traditional Oncology (대한암한의학회)
권호 표지
DOI QR코드

DOI QR Code

A Case Report of Patient with Metastatic Pancreatic Cancer Treated with modified Bangam-tang and Gunchil-dan in conjunction with Gemcitabine

전이 췌장암 환자의 Gemcitabine과 방암탕 가감방 및 건칠단 병용투여 치험 1례

  • Kim, Eun Hye (Department of Korean Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong) ;
  • Yoon, Sung Soo (Department of Korean Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong) ;
  • Lee, Jee Young (Department of Korean Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong) ;
  • Yoon, Seong Woo (Department of Korean Internal Medicine, Korean Medicine Cancer Center, Kyung Hee University Hospital at Gangdong)
  • 김은혜 (강동경희대학교 한방암센터 한방내과) ;
  • 윤성수 (강동경희대학교 한방암센터 한방내과) ;
  • 이지영 (강동경희대학교 한방암센터 한방내과) ;
  • 윤성우 (강동경희대학교 한방암센터 한방내과)
  • Received : 2018.11.27
  • Accepted : 2018.12.11
  • Published : 2018.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: This study was aimed to report a patient with metastatic pancreatic cancer treated with modified Bangam-tang and Gunchil-dan in conjunction with gemcitabine. There were better survival-related outcomes compared to gemcitabine alone. Methods: The patient with metastatic pancreatic cancer received gemcitabine as palliative chemotherapy since June 2016 concurrent with modified Bangam-tang and Gunchil-dan since October 2016 to October 2017. To evaluate the effect of treatment, tumor markers (carbohydrate antigen 19-9 (CA19-9) and carcinoembryonic antigen (CEA)), Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, and overall survival were checked. Adverse events were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Results: After 12 months with the combination treatment, levels of CA19-9 were decreased from 8747 to 265.7 ng/ml and CEA from 42.2 to 6.5 U/ml. Clinical partial response state was shown until May 2, 2017 and stable disease state was maintained from August 4, 2017. In March 2018, the patient got an operation including pancreatectomy and diagnosed with no evidence of disease state in September, 2018. In conclusion, it showed the overall survival of 29 months from June, 2016 to November, 2018. Serious adverse events were not identified. Conclusions: This study suggested that combined treatment with modified Bangam-tang and Gunchil-dan may show better outcome in patient with metastatic pancreatic cancer than gemcitabine alone.

Keywords

HJJJCF_2018_v23n2_1_f0001.png 이미지

Figure 1. Computed tomography image (A, B) Tumor masses in pancreas and liver on 2016-09-27 and 2017-10-10. The size of pancreatic lesion was remained from 2.6cm to 2.5cm and metastatic lesion of liver was disappeared in about 12 months. (C, D) Another metastatic tumor mass in liver on 2016-09-27 and 2017-10-10. The size was decreased from 6.2cm to 2.2cm. Each tumor was marked by white arrow.

HJJJCF_2018_v23n2_1_f0002.png 이미지

Figure 2. The change of tumor marker carbohydrate antigen 19-9 level

HJJJCF_2018_v23n2_1_f0003.png 이미지

Figure 3. The change of tumor marker carcinoembryonic antigen level

Table 1. Prescription of Herbal Medicine

HJJJCF_2018_v23n2_1_t0001.png 이미지

Table 2. The Change of Tumor Size in Computed Tomography Image per Every Three Months

HJJJCF_2018_v23n2_1_t0002.png 이미지

References

  1. The Korea Central Cancer Registry, National Cancer Center. Annual report of cancer statistics in Korea in 2015, Ministry of Health and Welfare, 2018
  2. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 371:1039-1049, 2014 https://doi.org/10.1056/NEJMra1404198
  3. Daniel D, Von H, Thoams E, Francis P, Chiorean E, Jeffrey I, Malcom M, Thoams S, Sergei A, Wen W, Mansoor N, Marion H, Michele R, Scot D, Daniel L, Nathan B, Ramesh K, Josep T, Manuel H, David G, Eric V, Xinyu W, Jose L, Markus F. Increase survival in pancreatic cancer with nab-Paclitaxel plsu Gemcitabine. N Engl J Med 3:1691-1703, 2013
  4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Pancreatic Adenocarcinoma. Version 1.2019 Available from: http/www.nccn.org/
  5. Lee JJ, Lee JJ. A phase II study of an herbal decoction that includes Astragali Radix for cancer-associated anorexia in patient with advenced cancer. Integr Cancer Ther 9:24-31, 2010
  6. Choi W, Jung H, Kim K, Lee S, Yoon S, Park J, Kim S, Cheon S, Eo W, Lee S. Rhus verniciflua stokes against advanced cancer: a perspective from the Korean Integrative Cancer Center. Biomed Res Int 2012:1-7, 2011
  7. Edge S, Compton C. AJCC Cancer Staging Manual 7th Edition. New York, Springer, 2010
  8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009 https://doi.org/10.1016/j.ejca.2008.10.026
  9. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 31:164-169, 2005 https://doi.org/10.1016/j.ejso.2004.09.007
  10. National Cancer Insitute. Common Terminology Criteria for Adverse Events, Version 5.0, revised March, 2018 Avaliable from:URL:https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
  11. Lund B, Kristjansen PE, Hansen HH. Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19:45-55, 1993
  12. Moore M, Goldstein D, Hamm J, Figer A, Hecht J, Gallinger S, Au H, Murawa P, Walde D, Wolff R, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007 https://doi.org/10.1200/JCO.2006.07.9525
  13. Garg AK, Buchholz TA, Aggarwal BB. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid Redox Signal 7:1630-1647, 2005 https://doi.org/10.1089/ars.2005.7.1630
  14. Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, Nishimura T, Mori Y, Masui T, Kawaguchi Y, Yanagihara K, Yazumi S, Chiba T, Guha S, Aggarwal BB. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 68:157-164, 2011 https://doi.org/10.1007/s00280-010-1470-2
  15. Lee S, Kim K, Jung H, Lee S, Cheon S, Kim S, Eo W, Choi W. Efficacy and safety of standardized allergen-removed Rhus verniciflua Stokes extract in patients with advanced or metastatic pancreatic cancer: a Korean single-center experience. Oncology 81:312-318, 2011 https://doi.org/10.1159/000334695
  16. 허준. 국역증보 동의보감. p.723, 서울, 남산당, 1998
  17. Tin M, Cho CH, Chan K, James AE, Ko J. Atragalus saponins induce growth inhibition and apoptosis in human colon cancer cells and tumor xenograft. Carcinogenesis 28:1347-1355, 2006
  18. Na D, Liu F, Miao ZF, Du ZM, Xu HM. Astragalus extract inhibits destruction of gastric cancer cells to mesothelial cells by anti-apoptosis. World J Gastroenterol 15:570-577, 2009 https://doi.org/10.3748/wjg.15.570